# Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer

> **NCT05078151** · NA · UNKNOWN · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 69 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DIAGNOSTIC_TEST:** Whole-Body Diffusion Weighted MRI

## Key facts

- **NCT ID:** NCT05078151
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078151, "Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05078151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*